Phase 3 Oesophageal Cancer Trial, Recruiting NCT05865743 Sponsor: Radboud University Medical Center Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 3 Oesophageal Cancer Trial, Recruiting

NCT05865743
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a specific type of esophageal cancer (adenocarcinoma or squamous cell carcinoma) located in the middle or lower part of the esophagus, or at the point where the esophagus meets the stomach, and who are scheduled for surgery to remove the esophagus or to rebuild it using part of the stomach or small intestine.
  • People aged 18 or older.
  • People who are able to read and sign a consent form agreeing to participate in the study.

Who may not be able to join:

  • People who are scheduled for emergency or "rescue" surgery rather than planned surgery.
  • People whose planned surgery involves using part of the large bowel (colon) to rebuild the esophagus.
  • People who are known or suspected to be pregnant.
  • People who have had surgery on their upper digestive system within the 30 days before being enrolled in the trial.
  • People who are unable to understand the study information or instructions, or who cannot give informed consent.
  • People who are already enrolled in another clinical trial that could interfere with this one.
  • People who have a known allergy, sensitivity, or harmful interaction with the study medication being tested.
  • People who have a documented presence of certain antibiotic-resistant bacteria (specifically Enterobacteriaceae or Pseudomonas Aeruginosa that do not respond to tobramycin/gentamicin or carbapenem antibiotics).
  • People who are undergoing a specific type of continuous kidney filtering treatment called CVVH (confirm with trial site).
  • People with documented severe chronic kidney failure, or who are on regular kidney dialysis (either haemodialysis or peritoneal dialysis).
  • Women who could become pregnant and are not using adequate contraception.
  • People who are unable to swallow the study medication, which is taken by mouth.
  • People who have a pre-existing degenerative neuromuscular condition, such as myasthenia gravis or Parkinson's disease.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Camiel Rosman, Prof, RadoudUMC

Phone: +31655740313

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
21 October 2024
Est. completion
31 December 2027

Where this trial is recruiting

🇧🇪 Belgium 🇳🇱 Netherlands

Primary endpoints

the cumulative incidence of postoperative pneumonia within 30 days after surgery

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov